Loading
Corvus Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Moore David Scott, was filed 15 Jun 2026.
Insider Decl.
169
Thresholds
n/a
Buy Volume
€47M
84 ops. · all time
Sell Volume
€48M
10 ops. · all time
Who traded when
BuySaleDavid Scott Moore1 buy
Orbimed Advisors LLC1 sale
Peter A. Thompson1 sale
Since the insiders bought
- -14.6%Entry US$11.74 · Close 21 Oct 2026 US$10.03
- +70.9%Entry US$1.96 · Close at T+365 US$3.35
- +70.9%Entry US$1.96 · Close at T+365 US$3.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.69
Analyst consensus
7 analysts1.13/5
US$27.00Target US$33.14(+242%)US$42.00
Income statement
EBITDA-US$42.9M
Net income-US$15.3M0.0% margin
Valuation
PER (forward)-9.1x
P/Book3.6x
Beta1.43
Balance sheet & cash
Market capUS$815.1M
Total debtUS$937k
Free Cash Flow-US$33M
Debt / Equity0%
Profitability & ownership
ROE-35.4%
ROA-21.7%
% insiders3.5%
% institutions85.8%
Last declaration on 15 June 2026
Declarations169 total
21,700 shares@ US$11.5316100.0% of flowCommon StockSEC:0001610717-26-000223:0
Canonical exit: 9 Sept 2026 (T+90)
15,000 shares@ US$9.700.4% of flowCommon StockSEC:0000947871-26-000079:1
15,000 shares@ US$12.500.5% of flowCommon StockSEC:0000947871-26-000079:2
15,000 shares@ US$3.610.1% of flowCommon StockSEC:0000947871-26-000079:3
15,000 shares@ US$2.000.1% of flowCommon StockSEC:0000947871-26-000079:4
15,000 shares@ US$3.270.1% of flowCommon StockSEC:0000947871-26-000079:5
15,000 shares@ US$2.740.1% of flowCommon StockSEC:0000947871-26-000079:6
15,000 shares@ US$2.600.1% of flowCommon StockSEC:0000947871-26-000079:7
15,000 shares@ US$0.98990.0% of flowCommon StockSEC:0000947871-26-000079:8
15,000 shares@ US$0.9650.0% of flowCommon StockSEC:0000947871-26-000079:9
15,000 shares@ US$2.490.1% of flowCommon StockSEC:0000947871-26-000079:10
15,000 shares@ US$1.640.1% of flowCommon StockSEC:0000947871-26-000079:11
15,000 shares@ US$2.120.1% of flowCommon StockSEC:0000947871-26-000079:12
30,000 shares@ US$15.003.6% of flowCommon StockSEC:0000947871-26-000079:0
1,176,332 shares@ US$4.158615.3% of flowCommon StockSEC:0000947871-25-000636:1
1,176,332 shares@ US$4.1612.3% of flowCommon StockSEC:0000947871-25-000635:1
1,397,684 shares@ US$3.5042.1% of flowCommon StockSEC:0000947871-25-000636:0
1,397,684 shares@ US$3.5040.5% of flowCommon StockSEC:0000947871-25-000635:0
19,357 shares@ US$3.5055.8% of flowCommon StockSEC:0001610717-25-000174:0
559,073 shares@ US$3.5059.9% of flowCommon StockSEC:0001610717-25-000115:0
302,016 shares0Common StockSEC:0001610717-24-000237:0
20,000 shares@ US$1.731230.2% of flowCommon StockSEC:0001610717-24-000232:0
Canonical exit: 4 Aug 2024 (T+90)
577,634 shares@ US$1.731232.1% of flowCommon StockSEC:0001610717-24-000231:0
Canonical exit: 4 Aug 2024 (T+90)
10,000 shares@ US$2.45100.0% of flowCommon StockSEC:0001610717-23-000041:0
Canonical exit: 13 Aug 2023 (T+90)
20,000 shares@ US$0.7914.0% of flowCommon StockSEC:0001567619-22-021876:0
Canonical exit: 20 Mar 2023 (T+90)
25 of 169 declarations
About Corvus Pharmaceuticals, Inc.
In 2016, Corvus Pharmaceuticals, Inc. generated 65 of its 154 filings, and two Novo purchases weigh heavily on their own: EUR 8,855,791 on March 29, 2016 by Novo A/S, then EUR 8,124,296 on March 12, 2018 under the name Novo Holdings A/S, both as a 10% owner. Peter A. Thompson (Director) bought EUR 7,306,035 on March 29, 2016. On March 12, 2018, 6 filers bought for EUR 25,063,454. Across the full history, 80 purchase filings are classed as clustered.
In all, 113 open-market purchases total EUR 72,904,867 (median EUR 55,089), against 8 sales worth EUR 40,077,943 (median EUR 4,366,702). The sales come mainly from EcoR1 Capital, LLC: EUR 13,072,817 on September 30, 2021, then EUR 8,570,583 on October 1, 2021, as a 10% owner. Purchases are 93% of trades.
Read moreShow less
Richard A. Miller MD (President and CEO) filed 46 filings including 40 purchases, Orbimed Advisors LLC (Director) 23. The US health care company is valued at USD 815.1 million. It has 12 filers and 2 filings over the last twelve months. For 104 purchases with a result, the 90-day median is 11.5%, with 53% of results positive (recorded past results, not a forecast).
